Status:
TERMINATED
Study of Diroximel Fumarate in the Real-World Setting
Lead Sponsor:
Biogen
Conditions:
Relapsing Forms of MS
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clini...
Eligibility Criteria
Inclusion
- Key
- Have a diagnosis of MS and satisfy the approved therapeutic indication for DRF per the USPI.
- DRF prescribed and planned to be initiated within 60 days after enrollment.
- Key
Exclusion
- History of gastric bypass or required use of feeding tubes.
- Have received prior treatment with DRF.
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 14 2023
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04746976
Start Date
March 1 2021
End Date
April 14 2023
Last Update
May 26 2023
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Regina Berkovich MD Phd Inc
West Hollywood, California, United States, 90048
2
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States, 20007
3
Norton Neuroscience Institute
Louisville, Kentucky, United States, 40207
4
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215